{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:00:56Z","timestamp":1774468856614,"version":"3.50.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Goals:<\/jats:title>\n                    <jats:p>Assess the safety and effectiveness of upadacitinib in patients with prior tofacitinib failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with severe, refractory Crohn\u2019s disease (CD) or ulcerative colitis (UC) and inadequate response to medical therapy have a high risk of complications. A better understanding of treatment response in the setting of prior failure may improve disease control in high-risk patients. Currently, the response to a subsequent Janus Kinase (JAK) inhibitor after prior JAK failure is poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study:<\/jats:title>\n                    <jats:p>We retrospectively assessed the safety and effectiveness of upadacitinib in patients with prior tofacitinib failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We report on 26 patients (10 UC, 16 CD) treated with upadacitinib after tofacitinib failure. Mean age 40.2 years, mean disease duration 14.4 years (range 2 to 33), and previously failed a median of 5 advanced therapies. The mean upadacitinib treatment duration was 13.9 months (SD 4.5). On upadacitinib, 83.3% (n=10\/12) of patients achieved clinical response, 66.7% (n=8\/12) clinical remission, 71.4% (n=10\/14) endoscopic improvement, 57.1% (n=8\/14) endoscopic remission, and 35.7% (n=5\/14) endoscopic healing. The mean Simple Endoscopic Score in CD decreased from 14.3 (SD: 8.3) to 8.6 (SD: 9.0) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.24). The mean Mayo Endoscopic Subscore significantly decreased from 2.7 (SD 0.8) to 0.9 (SD 1.2) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.006). 73.1% of patients on upadacitinib reported adverse events, most commonly minor infections and acne. No serious adverse events, major cardiovascular events, malignancies, or Shingles were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Upadacitinib was tolerated in most patients and resulted in clinical and endoscopic improvement in the majority of patients with severe, refractory CD or UC with prior tofacitinib failure, regardless of previous clinical response to tofacitinib. Further studies would define the long-term safety, efficacy, and predictors of response after previous JAK exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mcg.0000000000002157","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T13:08:28Z","timestamp":1741612108000},"page":"356-362","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Upadacitinib Results in Endoscopic Remission in Patients With Inflammatory Bowel Disease and Prior Tofacitinib Failure"],"prefix":"10.1097","volume":"60","author":[{"given":"Scott David","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra J.","family":"Kamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Harper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitra","family":"Barahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kindra Dawn","family":"Clark-Snustad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,4]]},"reference":[{"key":"R1-20260306","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","article-title":"Risk factors associated with progression to intestinal complications of Crohn\u2019s disease in a population-based cohort","volume":"139","author":"Thia","year":"2010","journal-title":"Gastroenterology"},{"key":"R2-20260306","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"R3-20260306","first-page":"727","article-title":"Are all Janus Kinase inhibitors for inflammatory bowel disease the same?","volume":"19","author":"Honap","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R4-20260306","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20260306","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"R6-20260306","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"R7-20260306","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"R8-20260306","doi-asserted-by":"crossref","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using bayesian network meta-analysis","volume":"5","author":"Panaccione","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"R9-20260306","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","article-title":"Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real-world data","volume":"21","author":"Boneschansker","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R10-20260306","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.14309\/ajg.0000000000002746","article-title":"One-year comparative effectiveness of upadacitinib vs tofacitinib for ulcerative colitis: a multicenter cohort study","volume":"119","author":"Dalal","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"R11-20260306","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/ibd\/izac247.155","article-title":"Use of upadacitinib in 16 tofacitinib-refractory ulcerative colitis patients: a single-center case 2series","volume":"29","author":"Levine","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R12-20260306","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2169\/internalmedicine.2653-23","article-title":"Efficacy of upadacitinib as a second-line JAK inhibitor in ulcerative colitis: a case series","volume":"63","author":"Hosomi","year":"2024","journal-title":"Intern Med"},{"key":"R13-20260306","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jamia\/ocz165","article-title":"Leaf: an open-source, model-agnostic, data-driven web application for cohort discovery and translational biomedical research","volume":"27","author":"Dobbins","year":"2019","journal-title":"J Am Med Inform Assoc"},{"key":"R14-20260306","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000002157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:00:35Z","timestamp":1772802035000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000002157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0000000000002157","relation":{},"ISSN":["1539-2031"],"issn-type":[{"value":"1539-2031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"2024-10-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}